Chem. J. Chinese Universities ›› 2009, Vol. 30 ›› Issue (4): 661.doi:

Previous Articles     Next Articles

Identified of Urinary Modified Nucleosides of Lymph Cancer Patients by HPLC/ESI-Q-TOF MS

LI Hua-Yu1, LIU Hong-Min2*, BU Shan-Shan1, LI Juan3, HAN Dong1, WU Guang-Yin4, WANG Shao-Min1, ZHANG Ming-Zhi5   

    1. Department of Chemistry,
    2. School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China;
    3. Organic Chemistry Laboratory, College of Huihua, Hebei Normal University, Shijiazhuang 050091, China;
    4. Oncology Department of the Henan Provincial People′s Hospital, Zhengzhou 450003, China;
    5. Oncology Department of the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450001, China
  • Received:2008-10-16 Online:2009-04-10 Published:2009-04-10
  • Contact: LIU Hong-Min, E-mail:liuhm@zzu.edu.cn

Abstract:

As modified nucleosides reflect altered tRNA turnover which is impaired in the body of cancer patients, they have been evaluated as potential tumor markers. High performance liquid chromatography(HPLC) was combined with full-scan mass spectrometry, MS/MS analysis and accurate mass measurements in order to identify modified nucleosides which purified from urine. Potential urinary nucleosides were assessed by their evident UV absorbance in the HPLC chromatogram and then further examined by the mass spectrometric techniques. In this manner the information of 9 nucleosides were reproduced with the standard compounds and 17 modified nucleosides without commercial standards were identified in the urine samples from lymph cancer patients including 6 novel urinary modified nucleosides: N3-methyladenosine, N7-methyladenine, 5′-dehydro-2′-deoxyinosine, N3-methylguanine, O6-methylguanosine and N7-methyl-N1-ethylguanosine. This new method is rapid and specific to identify the complex biological samples without control compounds.

Key words: HPLC/ESI-Q-TOF MS, Modified nucleosides, Lymph cancer, Urine

CLC Number: 

TrendMD: